Borealis Biosciences is a Canadian biotechnology company focused on developing next-generation RNA-based medicines for kidney diseases. The company leverages xRNA technology, which targets the body's natural mRNA to modulate protein production linked to disease. Borealis is backed by Novartis and Versant Ventures and has a strategic research collaboration with Novartis.

Borealis Biosciences

Senior Accountant

Research Associate I, Biology

Scientist, Translational Biology & Pharmacology

Borealis Biosciences Raises Additional $30M in Series A Financing - FinSMEs

Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding - Yahoo Finance

Versant’s Jerel Davis on build-to-buy deals and pharma investment - BioPharma Dive


              Scientist, Bioconjugation Chemistry
            

We’re excited to welcome Christian Hordo as our new CEO, along with a $30 million infusion from an extension of the Series A led by Westlake BioPartners and the addition of three new board directors, David Allison, Tom Frohlich and Catherine Thut.
 
With the Series A expansion, the company now has $180 million of capital to develop next-generation RNA medicines for kidney disease.  
 
Learn more at https://lnkd.in/gVA-2x7y

#biotech #RNA #kidneydisease

Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing

Borealis Biosciences, Inc. announced that it has received CAD 245.0644 million in funding from Versant Venture Management, LLC, Novartis AG, Westlake Village BioPartners - Marketscreener.com


              Scientist, Oligonucleotide Chemistry
            

Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing - Business Wire


              Sr. Research Associate, Oligonucleotide Chemistry
            

Biotech is Buzzing in Vancouver as 2024 Marks Year of Momentum for the Sector - Techcouver.com

Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding

Borealis Bio emerges from stealth with Versant and Novartis funding - The Pharma Letter

Wilson Sonsini Advises Borealis Biosciences on $150 Million Series A and Strategic Collaboration Funding - Wilson Sonsini

Novartis and Versant launch Borealis Biosciences with $150m - Yahoo Finance

Q3’24 Venture Pulse Report - Americas - KPMG

Vancouver Biotech Startup Emerges from Stealth with $150M to Combat Kidney Disease - Techcouver.com


              Protein Scientist, Biology
            

The biggest private biotech investments in August 2024 - Labiotech.eu

Borealis Biosciences Raises $150M in Series A Funding - FinSMEs

Borealis Biosciences

Business:

About: